(509) 228-1000 WA
(208) 754-3100 ID

Clinical Studies


The purpose of the study is to evaluate the efficacy, safety and tolerability of topically administered AG013 compared to placebo for reducing Oral Mucositis (OM) in patients undergoing chemoradiation for the treatment of head and neck cancer, as measured by the duration, time to development, and overall incidence of OM during the active treatment phase, beginning from the start of radiation therapy (RT) until 2 weeks following its completion.

The effect of AG013 on patient-reported symptoms and analgesic use during the active treatment phase, and on the cumulative radiation dose administered before the onset of OM will also be evaluated, as will biomarkers and, in a subset of subjects, the PK (pharmacokinetic) profile of AG013.

I Want to Participate

Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician. 

View Trial

For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:

  • Your name
  • Phone number & if we can leave a voice message at this number
  • Trial number(s) you are interested in
  • Name and city of clinic you are currently being treated